Article
Oncology
Idris Olasunmbo Ola, Kirsi Talala, Teuvo Tammela, Kimmo Taari, Teemu Murtola, Paula Kujala, Jani Raitanen, Anssi Auvinen
Summary: PSA-based screening can reduce prostate cancer mortality, but may also lead to overdetection of low-risk disease. The incidence of prostate cancer is associated with PSA levels, with higher PSA values indicating an increased risk of aggressive disease. Risk stratification and appropriate rescreening intervals can help reduce overdetection.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry R. Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte
Summary: Prostate-specific antigen (PSA) screening for prostate cancer remains controversial due to overdiagnosis and overtreatment. However, accounting for genetic determinants of PSA variation may improve screening accuracy.
Review
Andrology
Tushar Aditya Narain, Prasanna Sooriakumaran
Summary: PSA is a well-known biomarker used for screening, diagnosis, and follow-up of prostate cancer patients. Due to its limitations, newer blood and urinary biomarkers have been evaluated to improve detection and risk stratification. A combination of these markers, clinical risk factors, and advances in imaging offer the potential for better diagnostic performance and clearer risk stratification to guide therapeutics.
WORLD JOURNAL OF MENS HEALTH
(2022)
Article
Urology & Nephrology
Michael S. Leapman, Kimberly Stone, Roxanne Wadia, Lesley S. Park, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Maria Rodriguez-Barradas, Fatma Shebl, Amy C. Justice, Sheldon T. Brown, Kristina Crothers, Keith M. Sigel
Summary: The risk of prostate cancer among individuals living with human immunodeficiency virus (HIV) is not well understood. This study found that when accounting for less prostate-specific antigen (PSA) testing among HIV-positive individuals, the incidence of prostate cancer was similar to that of HIV-negative individuals.
JOURNAL OF UROLOGY
(2022)
Article
Medicine, General & Internal
Paul F. Pinsky, Howard Parnes
Summary: Screening for prostate cancer should take into consideration the risks and benefits. PSA screening can reduce prostate cancer deaths, but the reduction is small. Follow-up tests such as biopsy and MRI may be needed for individuals with elevated PSA levels. Patients with low-risk or favorable intermediate-risk prostate cancer may choose active surveillance over immediate curative treatment. Surgery and radiation therapy have good outcomes but can lead to complications.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Tomi Pakarainen, Jaakko Nevalainen, Kirsi Talala, Kimmo Taari, Jani Raitanen, Paula Kujala, Ulf-Hakan Stenman, Teuvo L. J. Tammela, Anssi Auvinen
Summary: The European Randomized Study of Screening for Prostate Cancer has shown that PSA-based screening can reduce prostate cancer mortality by 20% and lower the risk of advanced PC. Screening participation was found to increase the incidence of low-risk PC with the number of screens, while no clear relation was observed in intermediate and high-risk cases. Repeated screening is necessary to achieve the benefits of screening.
Article
Oncology
Sanny Kappen, Geertruida H. de Bock, Eunice Sirri, Claudia Vohmann, Joachim Kieschke, Alexander Winter
Summary: Prostate cancer is the most frequent cancer among men in Europe, with differences in incidence rates partly explained by variations in recommendations for PSA testing. A study comparing Lower Saxony in Germany and Groningen in the Netherlands found higher PCa incidence and lower PCa-related mortality in Lower Saxony. The data did not offer clear explanations for the observed differences, suggesting that further investigations are needed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Urology & Nephrology
K. Stinesen Kollberg, E. Holmberg, A. Josefsson, J. Hugosson, R. Arnsrud Godtman
Summary: The aim of this study was to describe the level of pre-testing and contamination in the Goteborg-1 prostate cancer screening trial. The results showed that similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Organized screening was found to be more effective in reducing prostate cancer mortality than non-organized testing.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Cara Reiter-Brennan, Omar Dzaye, Mouaz H. Al-Mallah, Zeina Dardari, Clinton A. Brawner, Lois E. Lamerato, Steven J. Keteyian, Jonathan K. Ehrman, Michael J. Blaha, Kala Visvanathan, Catherine H. Marshall
Summary: The study found that men with high fitness are more likely to undergo PSA screening and have a higher incidence of prostate cancer. However, men with high fitness have a lower risk of death after a prostate cancer diagnosis.
Article
Oncology
Danielle S. Bitterman, Ming-Hui Chen, Jing Wu, Andrew A. Renshaw, Marian Loffredo, Philip W. Kantoff, Eric J. Small, Anthony V. D'Amico
Summary: This study found that low testosterone level at PSA failure in high-risk patients with PC treated with RT is associated with increased PCSM and ACM risk, and that higher PSAn is also associated with worse PCSM and ACM risk, especially in men with normal testosterone levels at PSA failure.
Article
Oncology
Lauren M. Hurwitz, Nadine Dogbe, Kathryn Hughes Barry, Stella Koutros, Sonja Berndt
Summary: This study found that obesity indirectly increases the risk of prostate cancer mortality by affecting the efficacy of prostate cancer screening. Higher BMI was negatively associated with prostate cancer incidence but positively associated with prostate cancer mortality. However, this association was not influenced by screening outcomes.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Chemistry, Analytical
Yanbo Wang, Mingyang Wang, Haipeng Yu, Ge Wang, Pengxin Ma, Shuang Pang, Yiming Jiao, Aihua Liu
Summary: PSA is an important index for prostate cancer diagnosis and treatment. In this study, a biopanning method for PSA was established using a pIII phage display library. Two phage monoclonal antibodies specific to PSA were obtained, and an ELISA system was constructed for detecting tPSA with high accuracy.
SENSORS AND ACTUATORS B-CHEMICAL
(2022)
Article
Urology & Nephrology
Sebastiaan Remmers, Chris H. Bangma, Rebecka A. Godtman, Sigrid. Carlsson, Anssi Auvinen, Teuvo L. J. Tammela, Louis J. Denis, Vera Nelen, Arnauld Villers, Xavier Rebillard, Maciej Kwiatkowski, Franz Recker, Stephen Wyler, Marco Zappa, Donella Puliti, Giuseppe Gorini, Alvaro Paez, Marcos Lujan, Daan Nieboer, Fritz H. Schroeder, Monique J. Roobol
Summary: Based on the guidelines of the European Association of Urology, a risk-based strategy for prostate cancer screening should be determined by the first prostate-specific antigen (PSA) level and age. In this study, the baseline PSA level was found to guide decisions on the repeat screening interval and had an impact on prostate cancer detection and specific mortality rates.
Article
Urology & Nephrology
Maria Franlund, Marianne Mansson, Rebecka Arnsrud Godtman, Gunnar Aus, Erik Holmberg, Karin Stinesen Kollberg, Par Lodding, Carl-Gustaf Pihl, Johan Stranne, Hans Lilja, Jonas Hugosson
Summary: This study analyzed the results of the Goteborg randomized prostate cancer screening trial over 22 years and found that prostate specific antigen-based screening can significantly reduce prostate cancer mortality. However, not attending screening, starting after age 60, and stopping at age 70 may increase the risk of prostate cancer death.
JOURNAL OF UROLOGY
(2022)
Article
Medicine, General & Internal
Sue-Min Lai, John Keighley, Sarma Garimella, Mollee Enko, William P. Parker
Summary: This study evaluated the association of the 2008 and 2012 PSA screening guidelines with prostate cancer incidence by age and race and ethnicity in the US. The findings suggest that there were different patterns of prostate cancer incidence after the guideline changes among men of different age, race, and ethnicity groups.
Article
Oncology
Jonathan Parker, Danielle Crawley, Hans Garmo, Bertil Lindahl, Johan Styrke, Jan Adolfsson, Mats Lambe, Par Stattin, Mieke Van Hemelrijck, Kerri Beckmann
FRONTIERS IN ONCOLOGY
(2020)
Article
Health Care Sciences & Services
Elena Parmelli, Miranda Langendam, Thomas Piggott, Jan Adolfsson, Elie A. Akl, David Armstrong, Jeffrey Braithwaite, Romina Brignardello-Petersen, Markus Follmann, Zbigniew Les, Joerg J. Meerpohl, Luciana Neamtiu, Amir Qaseem, Paolo Giorgi Rossi, Zuleika Saz-Parkinson, Philip J. van der Wees, Holger J. Schuenemann
Summary: The research team proposed an integrated conceptual framework for guideline and QA development, clarifying terminology and definitions of key elements to guide the upcoming EU Colorectal Cancer Initiative. Through a mixed-method study involving multidisciplinary experts, the relationships and concepts of quality indicators, performance measures, and performance indicators in guideline-based QA were identified.
BMC HEALTH SERVICES RESEARCH
(2021)
Article
Health Care Sciences & Services
Thomas Piggott, Miranda Langendam, Elena Parmelli, Jan Adolfsson, Elie A. Akl, David Armstrong, Jeffrey Braithwaite, Romina Brignardello-Petersen, Jan Brozek, Jolanta Gore-Booth, Markus Follmann, Zbigniew Les, Joerg J. Meerpohl, Luciana Neamtiu, Monika Nothacker, Amir Qaseem, Paolo Giorgi Rossi, Zuleika Saz-Parkinson, Philip van der Wees, Holger J. Schuenemann
Summary: Through our research, we identified seven key themes to consider when integrating guidelines and quality assurance schemes, including: the feasibility of an integrated framework, the importance of transparency, the need to manage intellectual and financial interests appropriately, further refinement of selection processes and criteria for quality indicators, etc.
BMC HEALTH SERVICES RESEARCH
(2021)
Article
Oncology
E. Lin, Hans Garmo, Mieke Van Hemelrijck, Jan Adolfsson, Par Stattin, Bjorn Zethelius, Danielle Crawley
Summary: The study found a strong association between the use of GnRH and worsening diabetes control in men with T2DM and PCa.
Editorial Material
Medicine, General & Internal
Thomas Piggott, Miranda W. Langendam, Elena Parmelli, Jan Adolfsson, Elie A. Akl, David Armstrong, Jeffrey Braithwaite, Romina Brignardello-Petersen, Jan Brozek, Markus Follmann, Ina Kopp, Joerg J. Meerpohl, Luciana Neamtiu, Monika Nothacker, Amir Qaseem, Paolo Giorgi Rossi, Zuleika Saz-Parkinson, Philip J. van der Wees, Holger J. Schunemann
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Urology & Nephrology
Janet Athene Lane, Jenny L. Donovan, Grace J. Young, Michael Davis, Eleanor Walsh, Kerry N. L. Avery, Jane M. Blazeby, Malcolm D. Mason, Richard M. Martin, Tim J. Peters, Emma L. Turner, Julia Wade, Prasad Bollina, James W. F. Catto, Alan Doherty, David Gillatt, Vincent Gnanapragasam, Owen Hughes, Roger Kockelbergh, Howard Kynaston, Jon Oxley, Alan Paul, Edgar Paez, Derek J. Rosario, Edward Rowe, John Staffurth, David E. Neal, Freddie C. Hamdy, Chris Metcalfe
Summary: This study investigates the functional and quality of life outcomes of treatments for localized prostate cancer and provides valuable information for treatment decision-making. The findings show that men receiving active monitoring treatment experience gradual declines in sexual and urinary function with age, while radical treatments have immediate and continued impacts over 6 years. Furthermore, men treated with external-beam radiation therapy (EBRT) experience worse bowel function and bother compared to other treatments.
Article
Health Care Sciences & Services
Thomas Piggott, Miranda W. Langendam, Elena Parmelli, Jan Adolfsson, Elie A. Akl, David Armstrong, Jeffrey Braithwaite, Romina Brignardello-Petersen, Jan Brozek, Markus Follmann, Ina Kopp, Joerg J. Meerpohl, Luciana Neamtiu, Monika Nothacker, Amir Qaseem, Paolo Giorgi Rossi, Zuleika Saz-Parkinson, Philip J. van der Wees, Holger J. Schunemann
Summary: The study aimed to develop an extension of the GIN-McMaster Guideline Development Checklist and Tool for the integration of quality assurance and improvement (QAI) schemes with guideline development. A mixed-methods approach was used, incorporating evidence from a systematic review, an expert workshop, and a survey of experts. The result was a 40-item checklist extension, addressing steps for the integration of QAI into guideline development.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2023)
Article
Urology & Nephrology
Tiago M. Bonde, Marcus Westerberg, Markus Aly, Martin Eklund, Jan Adolfsson, Anna Bill-Axelson, Hans Garmo, Par Stattin, David Robinson
Summary: The objective of this study was to predict CRPC and Pca death using clinical variables and PSA levels. The results showed that post-GnRH PSA and ISUP grade were associated with the risk of CRPC and Pca death.
SCANDINAVIAN JOURNAL OF UROLOGY
(2022)
Editorial Material
Urology & Nephrology
Jan Adolfsson
SCANDINAVIAN JOURNAL OF UROLOGY
(2022)
Article
Medicine, General & Internal
E. Lin, Hans Garmo, Mieke Van Hemelrijck, Bjorn Zethelius, Par Stattin, Emil Hagstrom, Jan Adolfsson, Danielle Crawley
Summary: This study aimed to evaluate the association between GnRH agonist use, PCa diagnosis, and CVD risk in men with type 2 diabetes. The results showed that men with type 2 diabetes who received GnRH agonist for PCa had an increased risk of CVD and lower blood pressure levels.
Article
Oncology
E. Lin, Hans Garmo, Emil Hagstrom, Mieke Van Hemelrijck, Jan Adolfsson, Par Stattin, Bjorn Zethelius, Danielle Crawley
Summary: This study investigated the association between the use of GnRH in prostate cancer patients with type 2 diabetes mellitus and atherogenic dyslipidaemia. The results showed that GnRH treatment was associated with increased atherogenic lipids, indicating the need for caution when using GnRH in patients with diabetes.
BRITISH JOURNAL OF CANCER
(2023)
Review
Pediatrics
Jonas F. Ludvigsson, Jan Adolfsson, Malin Hoistad, Per-Anders Rydelius, Berit Kristroem, Mikael Landen
Summary: This systematic review aims to assess the effects of hormone treatment on psychosocial and mental health, cognition, body composition, and metabolic markers in children with gender dysphoria. The review identified 24 relevant English-language studies, but the evidence was insufficient to evaluate the effects of hormone therapy in these areas. Further research is needed to better understand the impacts of hormone treatment in children with gender dysphoria.
Article
Urology & Nephrology
Eugenio Ventimiglia, Anna Bill-Axelson, Jan Adolfsson, Markus Aly, Martin Eklund, Marcus Westerberg, Par Stattin, Hans Garmo
Summary: According to the study, the time spent in the CRPC state for men varies from 1.1 years for the highest risk category to 3.9 years for the lowest risk category. The proportion of men who died from prostate cancer within 10 years ranged from 93% for the highest risk category to 54% for the lowest. There was good agreement between the model estimates and observed data.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)
Review
Surgery
J. M. L. Rystedt, J. Wiss, J. Adolfsson, L. Enochsson, B. Hallerback, P. Johansson, C. Jonsson, P. Leander, J. Osterberg, A. Montgomery
Summary: The study demonstrates that routine IOC during cholecystectomy significantly reduces the risk of BDI and has the potential to be a cost-effective intervention.
Article
Urology & Nephrology
Marie Koitsalu, Martin Eklund, Jan Adolfsson, Mirjam A. G. Sprangers, Henrik Gronberg, Yvonne Brandberg
Summary: The study found that the STHLM3 test had minimal impact on the psychological well-being of men. Worry levels decreased in the low and intermediate risk groups, while no significant changes were observed in the high-risk group. Additionally, there were no changes in health-related quality of life over time.
EUROPEAN UROLOGY OPEN SCIENCE
(2021)